FAQ: Nutriband Inc.'s Financial Growth and AVERSA Fentanyl Development

What are Nutriband Inc.’s key financial results for the first half of 2025?

Nutriband reported revenue of $1.29 million for the six months ended July 31, 2025, representing a 50.87% year-over-year increase, and maintains cash reserves of $6.9 million to support product development.

What is AVERSA Fentanyl and why is it significant?

AVERSA Fentanyl is Nutriband’s lead abuse-deterrent transdermal fentanyl patch that could become the first and only product of its kind globally if approved, with peak annual sales estimated between $80 million and $200 million.

How does the AVERSA technology work?

AVERSA technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, though specific mechanisms are not detailed in the content.

What is the regulatory pathway for AVERSA Fentanyl approval?

The NDA for AVERSA Fentanyl will rely on data from a single Phase 1 Human Abuse Potential study, with no Phase 2 or Phase 3 trials required, and a Type C FDA meeting is scheduled for September 18, 2025.

What other products is Nutriband developing?

Nutriband is also developing AVERSA Buprenorphine, its second program, which is projected to reach peak annual sales of up to $130 million.

How is Nutriband generating revenue currently?

Nutriband continues to grow revenue through its Pocono Pharma contract manufacturing subsidiary, which contributed to the record first-half financial results.

Where can investors find more information about Nutriband?

The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB, and the full press release can be viewed at https://ibn.fm/spHiy.

What is the company’s website and primary business focus?

Nutriband’s website is www.nutriband.com, and the company is primarily engaged in developing a portfolio of transdermal pharmaceutical products with abuse-deterrent technology.